Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

McNeil OTC Nasalcrom three-year market exclusivity denial requested in citizen petition.

This article was originally published in The Tan Sheet

Executive Summary

McNEIL OTC NASALCROM THREE-YEAR MARKET EXCLUSIVITY DENIAL SOUGHT in a Jan. 13 citizen petition filed by the New York City law firm Bass & Ullman on behalf of an unnamed client that intends to market its own nonprescription cromolyn sodium 4% nasal solution for the prevention and treatment of allergic rhinitis. McNeil expects to launch Nasalcrom, which was approved by FDA Jan. 3, in time for the spring allergy season ("The Tan Sheet" Jan. 13, p. 1).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086674

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel